2024 Cisplatin accord fachinfo

Cisplatin accord fachinfo

Author: dkur

August undefined, 2024

WebCisplatină Accord, 1 mg/ml, concentrat pentru soluţie perfuzabilă Producător: Substanță activa Clasa ATC Format concentrat pentru soluţie perfuzabilă Afecțiuni diverse tipuri de cancer Producător Accord Healthcare Limited Acțiune terapeutică citostatice Cuprins Ce este Cisplatină Accord şi pentru ce se utilizează Web1. Mitä Cisplatin Accord 1 mg/ml on ja mihin sitä käytetään 2. Mitä sinun on tiedettävä, ennen kuin käytät Cisplatin Accord 1 mg/ml -valmistetta 3. Miten Cisplatin Accord 1 mg/ml -valmistetta käytetään 4. Mahdolliset haittavaikutukset 5. Cisplatin Accord 1 mg/ml -valmisteen säilyttäminen 6. Pakkauksen sisältö ja muuta tietoa 1.

Xircle • Cisplatin Accord 1 mg/ml Konzentrat zur Herstellung …

WebCisplatin Accord 1 mg/1 mL is available as a 10 mg/10 mL, 25 mg/25 mL, 50 mg/50 mL and 100 mg/100 mL solution for injection. For the full list of excipients, see . Section 6.1 List of Excipients. 3 PHARMACEUTICAL FORM . Solution for injection . Cisplatin Accord injection is a clear, colourless to pale yellow sterile solution of cisplatin 1 mg ... WebUnser Produktportfolio. Unser Portfolio umfasst zahlreiche Präparate aus verschiedensten Therapiegebieten wie etwa Onkologie & Hämatologie, Notfallmedizin, … heikung

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

WebCisplatin is only given by injection into a vein (an intravenous infusion). Supportive equipment should be available to control anaphylactic reactions. Cisplatin should not come into contact with any materials that contain aluminium. The recommended dosage of Cisplatin depends on your well-being, the Web/de/drugs/4LKkeHTvGRdBw2MF4IGVmoSGOy6/fluorouracil-accord-50-mg-ml-injektions-infusionslosung-20-ml WebCisplatin Accord® 10 mg/10 ml. Dosierung: 10 mg/10 ml. Darreichungsform: Durchstechflasche. Packungsgrösse: 1. Galenische Form: Konzentrat zur Herstellung … heikura hannes valokuvat

CISplatin Injection

WebCisplatin Injection is a clear, colorless to pale yellow, sterile aqueous solution. Each 50 mL or 100 mL amber vial of Cisplatin Injection contains: 1 mg/mL cisplatin, 9 mg/mL … WebFeb 1, 2003 · Cisplatină Accord se administrează numai prin injectare într-o venă (perfuzie intravenoasă). Echipamentul de asigurare a suportului trebuie să fie disponibil pentru a controla reacţiile anafilactice. Cisplatină Accord nu trebuie să vină în contact cu materiale care conţin aluminiu. heikuWebCisplatin Accord injection is a clear, colourless to pale yellow sterile solution of cisplatin 1 mg/mL and sodium chloride 9 mg/mL in water for injections. 4 CLINICAL PARTICULARS … heikura hyrynsalmi

"WebPemetrexed Accord in combination with cisplatin The recommended dose of Pemetrexed Accord is 500 mg/m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 BSA infused over two hours approximately 30 minutes after completion " - Cisplatin accord fachinfo

Cisplatin accord fachinfo

FACHINFORMATION Cisplatin Teva 1 mg / ml Konzentrat zur …

WebCisplatin Accord 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung. 2. QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG. 1 ml des Konzentrats zur Herstellung einer Infusionslösung enthält 1 mg Cisplatin. 10 ml des Konzentrats zur Herstellung einer Infusionslösung enthalten 10 mg Cisplatin. WebJun 8, 2024 · Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug. Neurologic symptoms have …

Did you know?

WebBehandlung mit Cisplatin eine aus-reichende Diurese zu gewährleisten. Für diesen Zweck wird die folgende Lösung intravenös infundiert: Natriumchloridlösung 0,9 % Art der … WebCisplatin for injection has been administered at 75 mg/m. 2 . to 100 mg/m. intravenously per cycle once every 3 to 4 weeks on Day 1. Other doses and combination regimens have …

WebKEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial, examined pembrolizumab with paclitaxel and cisplatin or paclitaxel and … WebA document describing the properties and the officially approved conditions of use of a medicine. Summaries of product characteristics form the basis of information for healthcare professionals on how to use the medicine safely and effectively. Abbreviated as SmPC.

Weboder bei mit Cisplatin vorbehandelten Patienten zu. Der Patient sollte neuro-logisch überwacht und in regelmä-ßigen Abständen neurologisch unter-sucht werden. Bei … WebCisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. CONTRAINDICATIONS Cisplatin is contraindicated in patients with preexisting renal impairment.

WebNov 30, 2024 · If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m 2 or more once every 3 to 4 weeks unless in the combination therapy of small-cell and non-small-cell lung carcinoma, in which a typical dose of 80 mg/m 2 is administered.

Web'lh hpsirkohqh 'rvlhuxqj yrq 'rfhwd[ho ehwuljw pj p dov vw qgljh ,qixvlrq jhirojw yrq &lvsodwlq pj p dov elv vw qgljh ,qixvlrq ehlgh qxu dq 7dj jhirojw yrq )oxrurxudflo pj p sur 7dj dov … heikyoku definitionWebApr 12, 2024 · Accord has cisplatin 1 mg/mL 50 mL and 100 mL vials on back order and the company cannot estimate a release date. Fresenius Kabi has cisplatin 1 mg/mL 50 … heiku lutterWebOm indlægssedlen 1. Virkning og anvendelse 2. Det skal du vide, før du begynder at bruge Cisplatin Accord 3. Sådan skal du bruge Cisplatin Accord 4. Bivirkninger 5. Opbevaring 6. Pakningsstørrelser og yderligere oplysninger Indehaver af markedsføringstilladelsen og fremstiller Oplysninger tiltænkt læger og sundhedspersonale Revisionsdato heila coilsWebJun 1, 2024 · A phase 2 trial of durvalumab in combination with gemcitabine and cisplatin demonstrated promising efficacy, with an objective response rate of 72% and a median overall survival of 20.2 months... heila'WebPage 7/10 Safety Data Sheet acc. to OSHA HCS Printing date 09/09/2024 Revision date 09/09/2024 Trade name:Cisplatin (Contd. from page 6) 53.1.21 · Primary irritant effect: · on the skin:No irritant effect. · on the eye:Strong irritant with the danger of severe eye injury. · Sensitization: Sensitization possible through inhalation. heila house heikyouWebCisplatin Solution Accord-UK Products Cisplatin Solution Active Ingredients Cisplatin Report a side effect or a product complaint Cisplatin 1mg/ml Concentrate for solution for … hei kuuraparta sanat